On The Fly
|
Check out this morning's… ShowHide Related Items >><< - 11/15/22
- Cathie Wood's ARK Investment bought 105K shares of XPeng
- 11/07/22
- XPeng rises 9.7%
- 11/01/22
- XPeng obtains autonomous driving test for G9
- 11/01/22
- Xpeng delivers 5,101 Smart EVs in October
- 11/30/22
- Petco announces partnership with Stella & Chewy's
- 11/30/22
- Petco jumps 13% to $10.76 after Q3 results, FY22 guidance
- 11/30/22
- Petco reports Q3 comparable sales growth of 4.1%
- 10/27/22
- Petco, Nationwide announce multi-year partnership
- 11/29/22
- Workday sees FY24 subscription revenue growth of 17%-19% to $6.5B-$6.6B
- 11/29/22
- Workday jumps 5% to $150.00 after Q3 results beat estimates
- 11/29/22
- Workday reports Q3 subscription revenue $1.43B, up 22.3% y/y
- 11/29/22
- Workday announces $500M share repurchase program
- 09/30/22
- Titan Machinery announces appointment of Larsen as CFO
- 07/11/22
- Titan Machinery to acquire Heartland Ag Systems for $110M
- 11/30/22
- Sanofi reports Phase II/III study results for acoziborole published in Lancet
- 11/17/22
- Provention Bio's Tzield approved by FDA for diabetes
- 09/29/22
- Leslie's publishes annual ESG report
- 09/28/22
- Leslie's to replace GCP Applied Technologies in S&P 600 at open on 9/28
- 07/14/22
- Leslie's opened 11 new stores in summer 2022
- 11/30/22
- AC Immune's ACI-35.030 selected for further development
- 11/22/22
- BeiGene to present final PFS results from ALPINE trial at ASH 2022
HZNP Horizon Therapeutics - 11/29/22
- Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi
- 11/29/22
- Horizon Pharma trading resumes
- 11/29/22
- Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi
- 11/29/22
- Horizon Pharma trading halted, news pending
- 09/12/22
- Oneok names Janet Hogan as Chief Human Resources Officer
- 08/09/22
- Hormel Foods announces new operating model
- 09/28/22
- Synaptogenix 'welcomes' Lecanemab Phase 3 trial results
- 09/27/22
- Eisai jumps 17% in early Tokyo trading after lecanemab data
- 09/27/22
- Biogen/Eisai's phase 3 trial of lecanemab in MCI meet primary endpoint
- 11/30/22
- Enbridge, OLCV to develop CO2 sequestration hub in Texas Gulf Coast
- 11/30/22
- Enbridge expects to deploy approximately C$6B of capital in 2023
- 11/30/22
- Enbridge raises quarterly dividend 3.2% to C$0.8875 per share
- 10/03/22
- Enbridge CEO Al Monaco to retire, Greg Ebel to succeed
- 08/31/22
- Donaldson sees FY23 CapEx $115M-$135M
- 06/14/22
- Donaldson acquires Purilogics for $20M plus milestones
- 06/01/22
- Donaldson sees FY22 CapEx $90M-$100M
- 06/01/22
- Donaldson CEO sees Q4 'sequential sales and gross margin improvement'
- 11/29/22
- Crowdstrike sees Q4 ARR below Q3 levels by up to 10%
- 11/29/22
- Crowdstrike falls 18% after Q3 results and guidance
- 09/20/22
- Crowdstrike to acquire external attack surface management firm Reposify
- 09/14/22
- CrowdStrike Appoints Jennifer Johnson as CMO
- 11/29/22
- Eisai and Biogen present full results for Lecanemab phase 3 study in AD
- 11/10/22
- Biogen names Viehbacher president, CEO
- 10/17/22
- Biogen announces FDA's 3-month expansion of review filing for NDA for tofersen
- 10/17/22
- Sage Therapeutics and Biogen present Phase 3 zuranolone results in depression
- 09/28/22
- Build-A-Bear announces release of NFT collection
- 07/26/22
- Cannell Capital discloses 10.7% activist stake in Build-A-Bear
- 07/08/22
- Kanen Wealth urges Build-A-Bear to 'take transformative action immediately'
- 11/14/22
- Greenlight takes new stake in Intel, exits position in Atlas Air
- 11/14/22
- AST SpaceMobile deploys commercial communications array in low Earth orbit
- 10/26/22
- AST SpaceMobile announces BlueWalker 3 test satellite update, Q3 results
- 09/15/22
- AST SpaceMobile down 8% to $9.38 after Kerrisdale release short report
- 11/22/22
- FDA investigating risk of severe hypocalcemia in patients receiving Prolia
- 11/09/22
- Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead
- 11/30/22 Mizuho
- Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
- 11/30/22 Jefferies
- Biogen price target raised to $350 from $325 at Jefferies
- 11/30/22 Wedbush
- Biogen price target raised to $247 from $218 at Wedbush
- 11/30/22 JPMorgan
- Biogen Alzheimer's data increases approval confidence, says JPMorgan
HZNP Horizon Therapeutics - 11/30/22 Cowen
- Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
- 11/30/22 Wells Fargo
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
- 11/01/22 H.C. Wainwright
- Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
- 10/25/22 Piper Sandler
- Horizon Therapeutics price target lowered to $88 from $90 at Piper Sandler
- 11/28/22 Wedbush
- Black Friday winners Include Best Buy, losers include Pets, says Wedbush
- 11/28/22 Needham
- Petco price target lowered to $20 from $30 at Needham
- 10/31/22 Citi
- Petco price target lowered to $15 from $19 at Citi
- 10/21/22 Jefferies
- Petco transferred with a Hold at Jefferies
- 08/25/22 Baird
- Titan Machinery price target raised to $34 from $27 at Baird
- 07/11/22 Baird
- Baird trims Titan Machinery price target to $27, but 'likes' Heartland Ag deal
- 05/27/22 Stephens
- Titan Machinery price target lowered to $41 from $44 at Stephens
- 05/26/22 Baird
- Titan Machinery price target raised to $32 from $30 at Baird
- 09/01/22 Baird
- Donaldson price target lowered to $59 from $61 at Baird
- 07/18/22 Stifel
- Donaldson price target lowered to $51 from $53 at Stifel
- 06/02/22 Baird
- Donaldson price target lowered to $61 from $65 at Baird
- 03/03/22 Baird
- Donaldson price target lowered to $65 from $70 at Baird
- 11/07/22 National Bank
- Enbridge downgraded to Sector Perform from Outperform at National Bank
- 10/20/22 Scotiabank
- Enbridge price target lowered to C$56 from C$62 at Scotiabank
- 10/19/22 Morgan Stanley
- Enbridge price target lowered to C$64 from C$67 at Morgan Stanley
- 09/12/22 Raymond James
- Enbridge upgraded to Outperform from Market Perform at Raymond James
- 11/28/22 Jefferies
- XPeng downgraded to Underperform at Jefferies ahead of 'challenging year'
- 11/28/22 Jefferies
- XPeng downgraded to Underperform from Hold at Jefferies
- 11/22/22 DBS Bank
- XPeng initiated with a Buy at DBS Bank (earlier)
- 11/17/22 UBS
- XPeng upgraded to Buy from Neutral at UBS
- 11/30/22 Deutsche Bank
- Workday price target lowered to $215 from $230 at Deutsche Bank
- 11/30/22 Baird
- Workday price target lowered to $223 from $235 at Baird
- 11/30/22 JPMorgan
- Workday price target lowered to $223 from $235 at JPMorgan
- 11/30/22 Mizuho
- Workday price target lowered to $200 from $220 at Mizuho
- 11/28/22 Stifel
- Leslie's price target lowered to $17 from $20 at Stifel
- 11/15/22 Baird
- Leslie's downgraded to Neutral from Outperform at Baird
- 10/03/22 MKM Partners
- MKM Partners starts Leslie's at Neutral, sees higher costs impact profitability
- 10/03/22 MKM Partners
- Leslie's initiated with a Neutral at MKM Partners
- 09/22/22 Argus
- Hormel Foods price target lowered to $53 from $54 at Argus
- 09/02/22 Piper Sandler
- Hormel Foods price target lowered to $47 from $48 at Piper Sandler
- 08/23/22 Stephens
- Hormel Foods price target raised to $55 from $50 at Stephens
- 03/15/22 Goldman Sachs
- Hormel Foods downgraded to Sell from Neutral at Goldman Sachs
- 11/30/22 Needham
- Crowdstrike price target lowered to $165 from $225 at Needham
- 11/30/22 DA Davidson
- Crowdstrike price target lowered to $145 from $235 at DA Davidson
- 11/30/22 MKM Partners
- Crowdstrike price target lowered to $190 from $200 at MKM Partners
- 11/30/22 Morgan Stanley
- Morgan Stanley says investors should 'buy the dip' in Crowdstrike after Q3
- 11/23/22 Deutsche Bank
- AST SpaceMobile price target raised to $32 from $30 at Deutsche Bank
- 10/28/22 B. Riley
- AST SpaceMobile initiated with a Buy at B. Riley
- 10/19/22 Barclays
- AST SpaceMobile price target lowered to $15 from $29 at Barclays
- 08/17/22 Deutsche Bank
- AST SpaceMobile price target lowered to $30 from $31 at Deutsche Bank
- 11/29/22 Craig-Hallum
- Craig-Hallum sees potential for competing Apollo Endosurgery bids
- 11/28/22 Morgan Stanley
- Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
- 11/17/22 Credit Suisse
- Johnson & Johnson initiated with a Neutral at Credit Suisse
- 11/17/22 Credit Suisse
- Amgen initiated with an Underperform at Credit Suisse
- 11/08/22 Oppenheimer
- Amgen price target raised to $300 from $290 at Oppenheimer
- 11/08/22 Truist
- Amgen price target raised to $280 from $266 at Truist
- 11/14/22 Oppenheimer
- Biogen price target raised to $315 from $300 at Oppenheimer
- 10/14/22 Barclays
- Sanofi price target lowered to EUR 85 from EUR 105 at Barclays
- 10/06/22 Jefferies
- Provention Bio price target raised to $15 from $10 at Jefferies
- 11/29/22 Jefferies
- Prothena data from AD/PD abstract 'promising,' says Jefferies
- 11/14/22 Jefferies
- Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
- 11/30/22
- XPeng sees Q4 revenue RMB 4.8B-RMB 5.1B
- 11/30/22
- XPeng reports Q3 EPS (36c), consensus (36c)
- 08/23/22
- XPeng sees Q3 revenue RMB6.8B-RMB7.2B, up 18.9%-25.9% from last year
- 08/23/22
- XPeng reports Q2 no-GAAP EPS (43c), consensus ($2.61)
- 11/30/22
- Petco cuts FY22 adjusted EPS view to 75c-79c from 77c-81, consensus 77c
- 11/30/22
- Petco reports Q3 adjusted EPS 16c, consensus 16c
- 11/29/22
- Notable companies reporting before tomorrow's open
- 11/29/22
- Workday raises low end of FY23 subscription revenue to $5.555B-$5.557B
- 11/29/22
- Workday reports Q3 adjusted EPS 99c, consensus 84c
- 11/29/22
- Notable companies reporting after market close
- 08/25/22
- Workday still sees FY23 suscription revenue up 22% y-o-y to $5.54B-$5.56B
- 11/30/22
- Titan Machinery raises FY23 EPS view to $4.55-$4.85 from $3.70-$4.00
- 11/30/22
- Titan Machinery reports Q3 EPS $1.82, consensus $1.16
- 08/25/22
- Titan Machinery raises FY23 EPS view to $3.70-$4.00 from $2.90-$3.20
- 08/25/22
- Titan Machinery reports Q2 adjusted EPS $1.10 vs. 53c a year ago
- 10/28/22
- Sanofi now sees 2022 business EPS growing 16% at CER
- 10/28/22
- Sanofi reports Q3 business EPS EUR 2.88, up 17.9% at CER
- 07/28/22
- Sanofi sees 2022 business EPS growing 15% at CER
- 07/28/22
- Sanofi reports Q2 business EPS EUR 1.73, up 16.7% at CER
- 11/30/22
- Leslie's sees 2023 adjusted EPS 78c-86c, consensus 93c
- 11/30/22
- Leslie's reports Q4 adjusted EPS 35c, consensus 31c
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
HZNP Horizon Therapeutics - 11/02/22
- Horizon Therapeutics sees FY22 revenue s $3.59B-$3.61B, consensus $3.56B
- 11/02/22
- Horizon Therapeutics reports Q3 EPS $1.25, consensus $1.01
- 08/03/22
- Horizon Therapeutics cuts FY22 revenue view to $3.53B-$3.6B from $3.9B-$4B
- 08/03/22
- Horizon Therapeutics reports Q2 adjusted EPS $1.07, consensus $1.35
- 11/30/22
- Hormel Foods reports Q4 EPS 51c, consensus 50c
- 11/30/22
- Enbridge sees FY23 EBITDA C$15.9B-C$16.5B, DCF C$5.25-C$5.65
- 11/30/22
- Enbridge backs FY22 adjusted EBITDA view in 'top half' of C$15B-C$15.6B
- 11/04/22
- Enbridge backs FY22 EBITDA view C$15B-C$15.6B
- 11/04/22
- Enbridge reports Q3 adjusted EPS C$0.67 vs. C$0.59 a year ago
- 11/30/22
- Donaldson sees FY23 adjusted EPS $2.91-$3.07, consensus $2.92
- 11/30/22
- Donaldson reports Q1 adjusted EPS 75c, consensus 71c
- 08/31/22
- Donaldson sees FY23 EPS $2.91-$3.07 , consensus $3.03
- 08/31/22
- Donaldson reports Q4 adjusted EPS 84c, consensus 84c
- 11/29/22
- Crowdstrike raises FY23 EPS view to $1.49-$1.52 from $1.31-$1.33
- 11/29/22
- Crowdstrike sees Q4 adjusted EPS 42c-45c, consensus 34c
- 11/29/22
- Crowdstrike reports Q3 adjusted EPS 40c, consensus 31c
- 10/25/22
- Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49
- 10/25/22
- Biogen reports Q3 adjusted EPS $4.77, consensus $4.15
- 10/24/22
- Notable companies reporting before tomorrow's open
- 11/30/22
- Build-A-Bear sees FY22 revenue $455M-$465M vs. $411.5M in FY21
- 11/30/22
- Build-A-Bear reports Q3 EPS 51c vs. 36c a year ago
- 08/15/22
- AST SpaceMobile reports Q2 EPS (6c) vs. (39c) last year
- 11/03/22
- Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00
- 11/03/22
- Amgen reports Q3 adjusted EPS $4.70, consensus $4.44
- 11/03/22
- Notable companies reporting after market close
- 08/04/22
- Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.40
|